X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/viatris-announces-us-fda-tentative-approval-of-a-paediatric-formulation-of-abacavir-abcdolutegravir-dtglamivudine-3tc-a-once-daily-treatment-for-children-living-with-hiv-301917144.html
https://www.ema.europa.eu/en/documents/overview/dovato-epar-medicine-overview_en.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-abacavir-sulfate-dolutegravir-and-lamivudine-tablets-52927.pdf
https://www.ema.europa.eu/en/documents/overview/dovato-epar-medicine-overview_en.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-delstrigo-doravirine-lamivudine-and-tenofovir-disoproxil-fumarate-27898.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216332
https://www.expresspharma.in/cipla-dndi-launch-4-in-1-antiretroviral-treatment-for-young-children-with-hiv-in-south-africa/
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213579
https://www.prnewswire.com/news-releases/rd-milestone-hebabiz-biotechs-application-for-phase-iii-clinical-trial-in-china-for-clevudine-l-fmau-an-anti-hepatitis-b-virus-drug-candidate-under-development-has-been-approved-301424127.html
https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/food-and-drug-administration-approved-revisions-triumeq-abacavirdolutegravirlamivudine-and-dovato
http://www.koreabiomed.com/news/articleView.html?idxno=9409
https://www.europeanpharmaceuticalreview.com/news/129913/dolutegravir-plus-lamivudine-shows-non-inferior-hiv-1-suppression-in-phase-iii-trials/
https://www.businesswire.com/news/home/20200923005300/en/Inflammasome-Therapeutics-Says-Study-of-Approximately-130000-People-Reported-in-Nature-Communications-Points-to-Potential-for-Treatment-or-Prevention-of-Diabetes-and-Other-Inflammasome-Mediated-Diseases-with-Company%E2%80%99s-Drugs
https://www.clinicaltrialsarena.com/news/viiv-dovato-hiv-1-data/
https://www.fiercepharma.com/marketing/gsk-viiv-s-dovato-wins-fiercemadness-dtc-ad-tournament-closest-contest-yet
https://www.fiercepharma.com/marketing/roche-ms-med-gsk-hiv-drug-new-tv-ads-top-november-charts-abbvie-humira
https://www.fiercepharma.com/marketing/gsk-s-viiv-launches-first-campaign-for-new-hiv-med-dovato-real-patients-who-are-more-than
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-dovato-211994-dolutegravir-sodium-and-lamivudinetablets-50-mg300-mg-1569474246.pdf
https://biospectrumindia.com/news/57/14753/mercks-pifeltro-and-delstrigo-get-fda-permission-to-treat-hiv-1-.html
https://www.biospace.com/article/merck-s-pifeltro-and-delstrigo-approved-in-hiv-patients-whose-disease-is-under-control/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-18-2019-1568770223.pdf
https://www.biospace.com/article/fda-action-alert-merck-and-amarin/
https://www.fiercepharma.com/marketing/viiv-hopes-dovato-new-data-could-ramp-up-uptake-hiv-2-drug-regimen
https://www.biospace.com/article/viiv-s-investigational-hiv-drug-hits-endpoints-in-difficult-to-treat-patient-population/
https://www.fiercepharma.com/manufacturing/fosun-snatches-gsk-plant-china-along-rights-to-make-epivir-generic?utm_source=internal&utm_medium=rss
https://in.reuters.com/article/us-gsk-hiv/gsks-dovato-meets-primary-goal-in-late-stage-hiv-study-idINKCN1U50KV
http://www.pharmatimes.com/news/viiv_secures_eu_nod_for_hiv_therapy_dovato_1293129
https://www.raps.org/news-and-articles/news-articles/2019/6/fda-plots-shift-away-from-csr-pilot-to-forge-new-t
https://www.raps.org/news-and-articles/news-articles/2019/5/fda-unveils-34-new-and-revised-product-specific-dr
https://www.reuters.com/article/us-gsk-dovato-ema/gsks-hiv-drug-wins-european-panel-thumbs-up-idUSKCN1S21RB?feedType=RSS&feedName=healthNews
https://endpts.com/viivs-dovato-wins-speedy-us-approval-with-prv-empowering-gsk-to-muscle-into-gileads-hiv-empire/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210899
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078545
https://www.raps.org/regulatory-focus/news-articles/2017/12/regulatory-explainer-everything-you-need-to-know-about-fdas-priority-review-vouchers?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2015%20February
https://health.economictimes.indiatimes.com/news/industry/laurus-labs-gets-usfda-nod-for-hiv-drug/67821291
https://www.fiercebiotech.com/research/decades-old-hiv-drug-might-help-treat-age-related-diseases
https://www.biospace.com/article/yale-researchers-discover-protein-in-the-immune-system-can-help-suppress-hiv/
https://www.reuters.com/article/us-indonesia-health-aids/indonesia-seeks-to-reassure-hiv-patients-over-drug-supplies-idUSKCN1P704I?feedType=RSS&feedName=healthNews
https://www.fiercepharma.com/pharma/jpm-wrapup-must-reads-from-a-week-biopharma-news-chosen-by-you
https://www.ema.europa.eu/documents/overview/delstrigo-epar-medicine-overview_en.pdf
Market Place
Share 
